Statin Pharmacogenomics: Lipid Response and Cardiovascular Outcomes

Current Cardiovascular Risk Reports

Volumn 4, Issue 2, 2010, Pages 150-158

  Kerola, Tuomas ^a   Lehtimäki, Terho ^b,c   Kähönen, Mika ^b,c   Nieminen, Tuomo ^a,c,d  

^a PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Pharmacogenetics; Pharmacogenomics; Statins

Indexed keywords

EID: 84855531506     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0081-0     Document Type: Review

References (48)

1. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005, 366: 1267-1278. (Published erratum appears in Lancet 2005, 366: 1358 and Lancet 2008, 371: 2084.).
2. Blum A, Shamburek R: The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203: 325-330.
3. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006, 6: 360-374.
4. Mangravite LM, Wilke RA, Zhang J, Krauss RM: Pharmacogenomics of statin response. Curr Opin Mol Ther 2008, 10: 555-561.
5. • Nieminen T, Kähönen M, Viiri LE, et al.: Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008, 9: 1475-1486. This is a recent review on apoE function and pharmacogenomics.
6. Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004, 177: 219-234.
7. • Polisecki E, Muallem H, Maeda N, et al.: Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008, 200: 109-114. This is a recent article regarding the genes LDLR and HMGCR within the PROSPER study. It is the first LDLR study with disease end points.
8. Boerwinkle E, Utermann G: Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 1988, 42: 104-112.
9. Kesäniemi YA, Ehnholm C, Miettinen TA: Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987, 80: 578-581.
10. Bennet AM, Di Angelantonio E, Ye Z, et al.: Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298: 1300-1311.
11. Abboud S, Viiri LE, Lutjohann D, et al.: Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. Eur J Hum Genet 2008, 16: 955-960.
12. Ilveskoski E, Perola M, Lehtimäki T, et al.: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999, 100: 608-613.
13. Nieminen T, Kähönen M, Lehtimäki T: The effects of apoA-I/C-III/A-IV, apoE and apoB polymorphisms on carotid artery intima-media thickness. Future Cardiol 2006, 2: 179-186.
14. Zintzaras E, Kitsios GD, Triposkiadis F, et al.: APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J 2009, 9: 248-257.
15. Mega JL, Morrow DA, Brown A, et al.: Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009, 29: 1310-1315.
16. Donnelly LA, Palmer CN, Whitley AL, et al.: Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 2008, 18: 279-287.
17. Gerdes LU, Gerdes C, Kervinen K, et al.: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000, 101: 1366-1371.
18. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al.: The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics 2002, 12: 647-653.
19. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al.: Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol 2006, 61: 327-331.
20. Chiodini BD, Franzosi MG, Barlera S, et al.: Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J 2007, 28: 1977-1983.
21. Ordovas JM, Cupples LA, Corella D, et al.: Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000, 20: 1323-1329.
22. Thompson A, Di Angelantonio E, Sarwar N, et al.: Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299: 2777-2788.
23. Boekholdt SM, Sacks FM, Jukema JW, et al.: Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13, 677 subjects. Circulation 2005, 111: 278-287.
24. Regieli JJ, Jukema JW, Grobbee DE, et al.: CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008, 29: 2792-2799.
25. Marschang P, Sandhofer A, Ritsch A, et al.: Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006, 260: 151-159.
26. Mohrschladt MF, van der Sman-de Beer F, Hofman MK, et al.: TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 2005, 13: 877-882.
27. •• Iakoubova OA, Tong CH, Rowland CM, et al.: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51: 435-443. This article gives the KIF6 results from the CARE and WOSCOPS studies.
28. •• Iakoubova OA, Sabatine MS, Rowland CM, et al.: Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2008, 51: 449-455. This article gives the KIF6 results from the PROVE-IT TIMI 22 study.
29. Libby P: Inflammation in atherosclerosis. Nature 2002, 420: 868-874.
30. Wight TN, Merrilees MJ: Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004, 94: 1158-1167.
31. •• Sabatine MS, Ploughman L, Simonsen KL, et al.: Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol 2008, 28: 562-567. Matrix metalloproteinase gene variation was linked to coronary events in CARE and WOSCOPS and pravastatin was particularly beneficial in the high-risk group.
32. Goodarzi MO, Taylor KD, Scheuner MT, et al.: Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J 2007, 7: 66-73.
33. Singer JB, Holdaas H, Jardine AG, et al.: Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 2007, 48: 2072-2078.
34. Donnelly LA, Doney AS, Dannfald J, et al.: A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008, 18: 1021-1026.
35. Krauss RM, Mangravite LM, Smith JD, et al.: Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008, 117: 1537-1544.
36. Lehtimäki T, Laaksonen R, Janatuinen T, et al.: Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men. Pharmacogenetics 2003, 13: 633-639.
37. Kunnas TA, Lehtimäki T, Laaksonen R, et al.: Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 2002, 80: 802-807.
38. Nieminen T, Knuuti J, Hämelahti P, et al.: Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol 2007, 47: 113-117.
39. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al.: Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004, 14: 53-60.
40. Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1: e97.
41. Maitland-van der Zee AH, Peters BJ, Lynch AI, et al.: The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenet Genomics 2009, 19: 338-344.
42. Polisecki E, Peter I, Robertson M, et al.: Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 2008, 200: 95-101.
43. Maitland-van der Zee AH, Boerwinkle E, Arnett DK, et al.: Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 2007, 153: 54-58.
44. Maitland-van der Zee AH, Lynch A, Boerwinkle E, et al.: Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C> T, MTHFR 1298 A> C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics 2008, 18: 651-656.
45. Hindorff LA, Lemaitre RN, Smith NL, et al.: Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics 2008, 18: 677-682.
46. Puccetti L, Pasqui AL, Bruni F, et al.: Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2007, 119: 41-47.
47. Puccetti L, Bruni F, Pasqui AL, et al.: Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia. Eur J Clin Invest 2008, 38: 11-16.
48. Couvert P, Giral P, Dejager S, et al.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008, 9: 1217-1227.